Dupixent's child benefit expands after over 1 1/2 yrs

Setting the standard after one year of application for enlargement

The will of the government and pharmaceutical companies is important

Discussions on expanding insurance benefits for children and adolescents of Dupixent, a treatment for atopic dermatitis, have been slow.

 

According to related industries, Sanofi-Aventis Korea's Dupixent 200mg passed the Drug Benefit Standards Subcommittee in May, but has yet to be submitted to the Drug Benefit Evaluation Committee.

 

The drug was applied for benefit expansion in March last year, but it is still in the early stages of the registration process.

 

Earlier, Dupixent spent seven months until the expert opinion inquiry began last year.

 

As it is an expensive new drug and it was not easy to register for the first time, it is believed that difficulties are also being followed in the discussion of expansion.

 

Although detailed indications are different, there is a clear difference in speed compared to JAK inhibitors such as Lilly Oluminant and Abbvie Rinvoq, which belatedly submitted applications for expansion of atopic benefits.

 

JAK inhibitors are also relatively inexpensive.

 

Both drugs have been reimbursed since May.

 

Since it is a risk-sharing agreement drug and a separate dose of 200mg has been added, it has to go through negotiations with the NHIS as well as HIRA's cost-effectiveness review process in the future.

 

It remains to be seen whether Dupixent will be able to reach an agreement with the government and expand child benefits.

 

Dupixent's health insurance coverage criteria are both 23 or higher EASI (Extremely severe eczema) even if symptoms are not controlled and systemic immunosuppressants are administered for more than 3 months, or if Dupixent is not available due to side effects.

 

This corresponds to 300 mg.